SCOPE

EQS-News: ENCAVIS AG: SCOPE affirms Encavis AG’s investment grade issuer rating ‘BBB-‘, and the Outlook remains ‘Positive’

Retrieved on: 
Thursday, July 27, 2023
Financial Oversight and Management Board for Puerto Rico, Private sector, GW, S-2, Policy, Power, Risk management, History, Outlook, Plant, EUR, IPP, EBITDA, Professional, Deutsch, Renewable energy, CFO, SCOPE, Growth, ESG, BB, MDAX, Security (finance)

Hamburg, 27 July 2023 – The Hamburg-based wind and solar park operator Encavis AG (Prime Standard; ISIN: DE0006095003, ticker symbol: ECV), listed on the MDAX of Deutsche Börse AG, and its financing subsidiary Encavis Finance BV have been rated again by the European rating agency SCOPE Ratings (SCOPE) affirming the investment grade issuer rating BBB-.

Key Points: 
  • Hamburg, 27 July 2023 – The Hamburg-based wind and solar park operator Encavis AG (Prime Standard; ISIN: DE0006095003, ticker symbol: ECV), listed on the MDAX of Deutsche Börse AG, and its financing subsidiary Encavis Finance BV have been rated again by the European rating agency SCOPE Ratings (SCOPE) affirming the investment grade issuer rating BBB-.
  • Concurrently, SCOPE has affirmed the ratings for senior unsecured debt at BBB-, subordinated (hybrid) debt at BB and short-term debt at S-2.
  • SCOPE has the opinion that the decreasing share of subsidised projects will likely be compensated by growing outreach and improving granularity of Encavis’ own portfolio.
  • To see the updated issuer report, as well as the rating history including SCOPE's initial public rating on Encavis AG and its debt-issuing subsidiary Encavis Finance BV on March 18, 2019, please click:

Securitize Expands Access to Hamilton Lane's Senior Credit Opportunities Fund via Polygon

Retrieved on: 
Thursday, May 4, 2023
Ethereum, Partnership, Information technology, Securitize, Inc., Polygon, Digital asset, SIPC, Risk, FINRA, SCOPE, Fund, Cryptocurrency, Bank, Security (finance), Financial services, Securitization

Hamilton Lane launched the Senior Credit Opportunities Fund ("SCOPE") in October 2022, and is now making a portion of the vehicle accessible to individual investors via a feeder fund from Securitize.

Key Points: 
  • Hamilton Lane launched the Senior Credit Opportunities Fund ("SCOPE") in October 2022, and is now making a portion of the vehicle accessible to individual investors via a feeder fund from Securitize.
  • The new tokenized fund is expected to broaden access to senior private credit, which has historically been a stable strategy through up and down markets.
  • The new feeder fund is the second in a series of three Hamilton Lane products being made available on the Securitize platform, following the launch of the Hamilton Lane Equity Opportunities Securitize Fund V in January.
  • To learn more about the Securitize Feeder - Hamilton Lane Senior Credit Opportunities Fund, visit: https://scope.securitize.io/ .

StudyKIK Awarded SCOPE Participant Engagement Award for Oncology Study Application and Best of Show for Patient Payment Platform, StudyCash

Retrieved on: 
Tuesday, February 28, 2023
Clinical trial, SCOPE, Patient, Nursing, Pharmaceutical industry

SANTA MONICA, Calif., Feb. 28, 2023 /PRNewswire-PRWeb/ -- StudyKIK, a leading provider of clinical trial technologies, was twice awarded for products making a positive impact in the clinical research industry at the 2023 Summit for Clinical Ops Executives (SCOPE), a conference focused on advancing innovative solutions in all aspects of clinical trial innovation and management.

Key Points: 
  • StudyKIK's Oncology Study App was awarded the Participation Engagement Award, an accolade recognizing innovation and change in how the clinical research industry communicates with participants in the fields of recruitment and retention in clinical trials.
  • More than 3,000 attendees voted on best new products in the clinical trial and research space and selected StudyCash, StudyKIK's new patient payment platform, as a recipient of the Best of Show Award.
  • "It's an incredible feeling to have our hard work and dedication recognized at SCOPE 2023," said Greg Christie, Chief Product Officer of StudyKIK.
  • Receiving the Participant Engagement Award for our oncology app and Best in Show for StudyCash, our new patient payment solution, is validation of our mission to transform the study experience with innovative, empathetic and thoughtful technology."

Celsius Therapeutics to Present Preclinical Data on Anti-TREM1 Antibody at 18th Congress of ECCO - Inflammatory Bowel Diseases

Retrieved on: 
Monday, February 27, 2023
Oncology, Health, FDA, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Congress, B cell, Therapy, Cancer, TREM1, Inflammation, Patient, Biology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Trial of the century, Inflammatory bowel disease, ECCO, Inflammatory Bowel Diseases, European, SCOPE, IBD, Food, RNA, Pharmaceutical industry, Celsius

Celsius Therapeutics, a biotechnology company pioneering new precision medicines for patients with cancer and inflammatory disease by harnessing the power of single-cell RNA sequencing and human biology at scale, today announced that new data on CEL383, a potential first-in-class anti-TREM1 antibody for the treatment of inflammatory bowel disease (IBD), has been selected for a digital oral presentation at the 18th Congress of ECCO - Inflammatory Bowel Diseases, hosted by the European Crohn’s and Colitis Organisation from March 1-4, 2023, in Copenhagen, Denmark.

Key Points: 
  • Celsius Therapeutics, a biotechnology company pioneering new precision medicines for patients with cancer and inflammatory disease by harnessing the power of single-cell RNA sequencing and human biology at scale, today announced that new data on CEL383, a potential first-in-class anti-TREM1 antibody for the treatment of inflammatory bowel disease (IBD), has been selected for a digital oral presentation at the 18th Congress of ECCO - Inflammatory Bowel Diseases, hosted by the European Crohn’s and Colitis Organisation from March 1-4, 2023, in Copenhagen, Denmark.
  • “We are thrilled to present insights identified through our SCOPE platform (Single Cell Observations for Precision Effect) that point to an important role for TREM1 in inflammatory bowel disease and led to the initiation of our CEL383 program at ECCO 2023,” said Tariq Kassum, M.D., President and CEO of Celsius.
  • “We anticipate filing an investigational new drug application for CEL383 with the U.S. Food and Drug Administration and commencing a Phase 1 clinical study in the first half of this year.”

ObjectiveHealth Unveils ObjectiveView, a Technology Portal Giving Clinical Trial Sponsors Unprecedented Data Access

Retrieved on: 
Tuesday, February 14, 2023
Research, Technology, Hospitals, Clinical Trials, Health Technology, Software, Practice Management, Managed Care, Health, Science, Clinical trial, Running, SCOPE, Patient, Pharmaceutical industry

ObjectiveHealth , an integrated research and technology platform company, today announced the launch of ObjectiveView , a technology portal that provides the sponsors of clinical trials with an unprecedented level of transparency into the process.

Key Points: 
  • ObjectiveHealth , an integrated research and technology platform company, today announced the launch of ObjectiveView , a technology portal that provides the sponsors of clinical trials with an unprecedented level of transparency into the process.
  • Clinical trial sponsors are invested in the process of running trials but are rarely in the loop about their day-to-day progress.
  • ObjectiveView changes that by offering real-time access to recruitment and trial data that have not historically been available, providing valuable insights along the way.
  • “Challenges can present themselves at every stage of a clinical trial, and ObjectiveView provides an opportunity for sponsors to address potential trends that could lead to a slowdown,” said Josh O’Rourke , chief technology officer of ObjectiveHealth.

Medidata Experts Present New Insights on Risk-Based Quality Management, Decentralized Clinical Trials, and Real World Data at SCOPE Summit

Retrieved on: 
Friday, February 3, 2023
Biotechnology, Pharmaceutical, Oncology, General Health, Health, FDA, Clinical Trials, Other Health, Count key data, Acceleration, Financial impact of the Boeing 737 MAX groundings, Intelligence, Bayer, Melissa, DCT, Dassault Group, Russian Industrial Leaders Index, Clinical trial, Research, Parexel, Risk, Financial management, SCOPE, R&D, Professional services, R, Success, Pharmaceutical industry, Management, Medidata Solutions

Medidata , a Dassault Systèmes company, will be leading multiple sessions at the upcoming Summit for Clinical Ops Executives (SCOPE) on trial diversity, risk based quality management (RBQM), decentralized clinical trials (DCT), real world data, sensors and wearables, and randomization and trial supply management (RTSM).

Key Points: 
  • Medidata , a Dassault Systèmes company, will be leading multiple sessions at the upcoming Summit for Clinical Ops Executives (SCOPE) on trial diversity, risk based quality management (RBQM), decentralized clinical trials (DCT), real world data, sensors and wearables, and randomization and trial supply management (RTSM).
  • Medidata is a top signature sponsor of the event held February 6-9.
  • “We are passionate about patient-focused, data-driven clinical operations, from study feasibility, to financial management to risk based quality management,” said Fareed Melhem, senior vice president Medidata AI.
  • SCOPE 2023 Presentations: In addition to the featured presentations below, Medidata will also be moderating several breakout tracks, and chairing the clinical supply and med device trials tracks.

Greenphire CEO to Join Pharma and Research Industry Experts to Address Clinical Trial Patient Pain Points During 14th Annual SCOPE Summit

Retrieved on: 
Tuesday, February 7, 2023
Transport, Research, Critical Role, Merck, Travel, SCOPE, ChromeOS, Workload, Clinical trial, Pharmaceutical industry

ORLANDO, Fla., Feb. 7, 2023 /PRNewswire/ -- Greenphire, the global leader in financial lifecycle management for clinical trials, today announced that Greenphire CEO, Jim Murphy, will participate in the panel session "The Critical Role of Planning and Budgeting for Patient Logistics," and will be exhibiting at booth #406 during SCOPE Summit 2023 taking place February 6-9, 2023 in Orlando.

Key Points: 
  • The co-presenters in the session include:
    Kelly White, Senior Director, Head of Global Trial Optimization, Oncology from Merck
    Clinical research sponsors and CROs are increasingly leveraging patient convenience solutions to remove the burden of participating in study visits.
  • "I am honored to join a panel of experts from both research and pharma sectors to discuss the important topic of how the industry can deliver on an optimal patient engagement strategy," said Murphy.
  • Companies are looking to maximize convenience and accessibility for study participants, without creating increased workload for research sites.
  • Learn more about our presence at SCOPE Summit 2023 and engage with us on our show page: http://bit.ly/3jiE9qi .

ScienceMedia Breaks Down Barriers to Bringing More Diverse Patient Populations to Clinical Trials

Retrieved on: 
Monday, February 6, 2023
SMI, Trust, Safety, Language, James Surls, Patient, Clinical trial, Health equity, Blog, Education, SAN, SCOPE, Nursing

SAN DIEGO, Feb. 6, 2023 /PRNewswire/ -- SMi Trial™ , ScienceMedia's protocol compliance and risk-based training solution for clinical trials, now supports diversity in clinical trials.

Key Points: 
  • SAN DIEGO, Feb. 6, 2023 /PRNewswire/ -- SMi Trial™ , ScienceMedia's protocol compliance and risk-based training solution for clinical trials, now supports diversity in clinical trials.
  • To premiere at SCOPE 2023 in Orlando, FL, SMi Trial incorporates patient facing training for trial recruitment with content focused on diverse and underrepresented populations that are typically naïve to clinical trial participation.
  • ScienceMedia CEO, Mark Surles, Ph.D., shares, "The barriers to bring a more diverse patient population to clinical trials is a real issue.
  • SMi Trial's trusted protocol-specific patient education fosters trust in clinical trials, increases study awareness, and improves health equity.

Announcing the Launch of The Association of Diversity in Clinical Trials

Retrieved on: 
Friday, February 3, 2023
US, Health equity, Government, SCOPE, AOD, Macrocephaly, Surgeon General of the United States, Advisory board, Pharmaceutical industry, Nursing

DALLAS, Feb. 3, 2023 /PRNewswire/ -- The Association of Diversity in Clinical Trials (AOD) is being launched and introduced at upcoming industry conferences SCOPE and the Health Equity in Clinical Trials Congress this month.

Key Points: 
  • DALLAS, Feb. 3, 2023 /PRNewswire/ -- The Association of Diversity in Clinical Trials (AOD) is being launched and introduced at upcoming industry conferences SCOPE and the Health Equity in Clinical Trials Congress this month.
  • The AOD will become the first entity to represent industry in an effort to meet new government and regulatory demands in the field of diversity.
  • This will be achieved through the development, integration, and monitoring of quality and consistent diversity methodology across the research industry.
  • A prestigious Advisory Board of leaders will be announced soon who will support this unprecedented step towards the assurance of representative diversity and inclusion in clinical trials.

Atreo Advances its Mission to Modernize RTSM with v1.2 Product Release

Retrieved on: 
Wednesday, February 1, 2023
SAN, Booth, SME, SCOPE, Drug, Industrial design

SAN FRANCISCO, Feb. 1, 2023 /PRNewswire/ -- Atreo, Inc., a Clinical Development SaaS company committed to modernizing and simplifying RTSM delivery, has announced release of v1.2 of their next generation platform in advance of SCOPE 2023.  

Key Points: 
  • "Interest from clinical teams in our next generation RTSM solution has been encouraging to say the least.
  • We have been privileged to collaborate with numerous forward-thinking sponsors and CROs who have embraced our unique and streamlined approach to RTSM delivery.
  • We are greatly appreciative of their partnerships and eager to support future clinical teams in modernizing their RTSM experiences."
  • Experience the Future of RTSM:  Visit Atreo's Team of Experts at Booth 334 for a Demonstration of our Next-Generation Solution.